Excellent thread on cilta-cel, only point I would highlight is if you progress on bridging therapy, your risk of fatal outcome 🔝 and in that situation I would not proceed directly with cilta cel but consider other options to lower disease burden!
#mmsm
How to counsel patients about Cilta Cel using the data from
CARTITUDE-4 and FDA ODAC meeting for earlier use
With data of Cilta cel and Ide cel, assuming having access to both for a given patient, I will personally chose Cilta cel (I explained this before)
🧵